{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:31:58Z","timestamp":1783603918717,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371042"],"award-info":[{"award-number":["81371042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant from Shanghai Hospital Development Center","award":["SHDC12016116"],"award-info":[{"award-number":["SHDC12016116"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00262-018-2260-7","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T05:54:45Z","timestamp":1539237285000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Ching","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-8432","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"issue":"2","key":"2260_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151","journal-title":"Immunity"},{"issue":"7","key":"2260_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","volume":"19","author":"T Okazaki","year":"2007","unstructured":"Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19(7):813\u2013824. https:\/\/doi.org\/10.1093\/intimm\/dxm057","journal-title":"Int Immunol"},{"issue":"8","key":"2260_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"issue":"49","key":"2260_CR4","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101(49):17174\u201317179. https:\/\/doi.org\/10.1073\/pnas.0406351101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2260_CR5","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104(9):3360\u20133365. https:\/\/doi.org\/10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2260_CR6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089\u20131096","journal-title":"Cancer Res"},{"issue":"4","key":"2260_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"21","key":"2260_CR8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"24","key":"2260_CR9","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, IMpower150 Study Group (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"2260_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"issue":"4","key":"2260_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","volume":"17","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A, Schob O, Giryes A (2017) Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther 17(4):387\u2013394. https:\/\/doi.org\/10.1080\/14737140.2017.1296765","journal-title":"Expert Rev Anticancer Ther"},{"key":"2260_CR12","unstructured":"U.S. Department of Health and Human Services (2010) Common terminology criteria for adverse events (CTCAE) version 4.03. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf#search=%2711.+U.S.DEPARTMENT+OF+HEALTH+AND+HUMAN+SERVICES.+Common+Terminology+Criteria+for+Adverse+Events+%28CTCAE%29+Version+4.03%3A+June+14%2C+2010%27 . Accessed 15 July 2018"},{"issue":"10","key":"2260_CR13","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","volume":"23","author":"AW Taylor","year":"2009","unstructured":"Taylor AW (2009) Ocular immune privilege. Eye 23(10):1885\u20131889. https:\/\/doi.org\/10.1038\/eye.2008.382","journal-title":"Eye"},{"key":"2260_CR14","doi-asserted-by":"publisher","unstructured":"Zhou R, Caspi RR (2010) Ocular immune privilege. F1000 Biol Rep 2. https:\/\/doi.org\/10.3410\/B2-3","DOI":"10.3410\/B2-3"},{"issue":"1","key":"2260_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/09273940802491884","volume":"17","author":"L Chen","year":"2009","unstructured":"Chen L, Pai V, Levinson R, Sharpe AH, Freeman GJ, Braun J, Gordon LK (2009) Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm 17(1):47\u201355. https:\/\/doi.org\/10.1080\/09273940802491884","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"2260_CR16","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.4049\/jimmunol.177.9.5928","volume":"177","author":"J Hori","year":"2006","unstructured":"Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, Okumura K, Yagita H, Azuma M (2006) B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 177(9):5928\u20135935","journal-title":"J Immunol"},{"key":"2260_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N (2016) PD-1\/PD-L and autoimmunity: a growing relationship. Cell Immunol 310:27\u201341. https:\/\/doi.org\/10.1016\/j.cellimm.2016.09.009","journal-title":"Cell Immunol"},{"issue":"6","key":"2260_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1189\/jlb.3A1014-466RR","volume":"97","author":"DJ Lee","year":"2015","unstructured":"Lee DJ, Taylor AW (2015) Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J Leukoc Biol 97(6):1101\u20131109. https:\/\/doi.org\/10.1189\/jlb.3A1014-466RR","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2260_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12886-017-0611-3","volume":"17","author":"C Theillac","year":"2017","unstructured":"Theillac C, Straub M, Breton AL, Thomas L, Dalle S (2017) Bilateral uveitis and macular edema induced by Nivolumab: a case report. BMC Ophthalmol 17(1):227. https:\/\/doi.org\/10.1186\/s12886-017-0611-3","journal-title":"BMC Ophthalmol"},{"key":"2260_CR20","doi-asserted-by":"publisher","DOI":"10.21767\/2471-8041.100044","author":"DM Baughman","year":"2017","unstructured":"Baughman DM, Lee CS, Snydsman BE, Jung HC (2017) Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. Med Case Rep (Wilmington). https:\/\/doi.org\/10.21767\/2471-8041.100044","journal-title":"Med Case Rep (Wilmington)"},{"issue":"5","key":"2260_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O (2017) Vogt\u2013Koyanagi\u2013Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5(5):694\u2013700. https:\/\/doi.org\/10.1002\/ccr3.911","journal-title":"Clin Case Rep"},{"issue":"7","key":"2260_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.18240\/ijo.2017.07.28","volume":"10","author":"DR Richardson","year":"2017","unstructured":"Richardson DR, Ellis B, Mehmi I, Leys M (2017) Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol 10(7):1183\u20131186. https:\/\/doi.org\/10.18240\/ijo.2017.07.28","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"2260_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jiac.2017.04.007","volume":"23","author":"H Kanno","year":"2017","unstructured":"Kanno H, Ishida K, Yamada W, Nishida T, Takahashi N, Mochizuki K, Mizuno Y, Matsuyama K, Takahashi T, Seishima M (2017) Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J Infect Chemother 23(11):774\u2013777. https:\/\/doi.org\/10.1016\/j.jiac.2017.04.007","journal-title":"J Infect Chemother"},{"issue":"8","key":"2260_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","volume":"44","author":"T Arai","year":"2017","unstructured":"Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R (2017) Case of acute anterior uveitis and Vogt\u2013Koyanagi\u2013Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 44(8):975\u2013976. https:\/\/doi.org\/10.1111\/1346-8138.13612","journal-title":"J Dermatol"},{"issue":"2","key":"2260_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/09273948.2016.1215473","volume":"26","author":"J Karlin","year":"2018","unstructured":"Karlin J, Gentzler R, Golen J (2018) Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 26(2):283\u2013285. https:\/\/doi.org\/10.1080\/09273948.2016.1215473","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"2260_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/art.39406","volume":"68","author":"G Velasco de","year":"2016","unstructured":"de Velasco G, Bermas B, Choueiri TK (2016) Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 68(2):556\u2013557. https:\/\/doi.org\/10.1002\/art.39406","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2260_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","volume":"11","author":"MT Aaberg","year":"2017","unstructured":"Aaberg MT, Aaberg TM Jr (2017) Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 11(4):348\u2013351. https:\/\/doi.org\/10.1097\/ICB.0000000000000368","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"2260_CR28","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jcjo.2015.09.008","volume":"51","author":"A Basilious","year":"2016","unstructured":"Basilious A, Lloyd JC (2016) Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol 51(1):e4\u2013e6. https:\/\/doi.org\/10.1016\/j.jcjo.2015.09.008","journal-title":"Can J Ophthalmol"},{"issue":"11","key":"2260_CR29","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1002\/phar.1839","volume":"36","author":"KS Hanna","year":"2016","unstructured":"Hanna KS (2016) A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy 36(11):e183\u2013e188. https:\/\/doi.org\/10.1002\/phar.1839","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2260_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CJI.0000000000000143","volume":"39","author":"S Diem","year":"2016","unstructured":"Diem S, Keller F, Ruesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L (2016) Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother 39(9):379\u2013382. https:\/\/doi.org\/10.1097\/CJI.0000000000000143","journal-title":"J Immunother"},{"issue":"3","key":"2260_CR31","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.5301\/ejo.5000724","volume":"26","author":"K Abu Samra","year":"2016","unstructured":"Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD (2016) A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 26(3):e46\u2013e48. https:\/\/doi.org\/10.5301\/ejo.5000724","journal-title":"Eur J Ophthalmol"},{"key":"2260_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166\u2013182. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00662.x","journal-title":"Immunol Rev"},{"issue":"8","key":"2260_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"26","key":"2260_CR34","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"26","key":"2260_CR35","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465. https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"issue":"2","key":"2260_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133. https:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"},{"issue":"7","key":"2260_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700\u2013712. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"issue":"21","key":"2260_CR38","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T20:00:54Z","timestamp":1662235254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2260-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"21 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}